Industry news, page-1775

I am guessing combinations are well know and licensing in place , except Race endeavours;
Exploring novel combinations with bisantrene for synergistic effects in cancer treatment is a promising approach. Here are some potential combinations based on their mechanisms and preclinical evidence:1. **Bisantrene and Hypomethylating Agents**: - **Decitabine**: As already being investigated by Race Oncology for AML, combining bisantrene with decitabine has shown enhanced anticancer activity in preclinical models [oai_citation:1,Race Executes Contract to Commence Phase 2 Extramedullary AML Trial – Race Oncology](https://raceoncology.com/race-executes-contract-to-commence-phase-2-extramedullary-aml-trial/) [oai_citation:2,ASX:RAC - Bisantrene with Decitabine Enhances Cancer Cell Killing](https://announcements.raceoncology.com/announcements/6334252).2. **Bisantrene and Checkpoint Inhibitors**: - **Pembrolizumab or Nivolumab**: These immune checkpoint inhibitors could potentially boost the immune response when combined with bisantrene, especially in cancers where immune evasion is a key factor.3. **Bisantrene and Other Epigenetic Modifiers**: - **Vorinostat (HDAC Inhibitor)**: Combining bisantrene with histone deacetylase inhibitors might enhance its ability to modulate gene expression and suppress cancer cell growth.4. **Bisantrene and Proteasome Inhibitors**: - **Bortezomib**: This combination could be effective in multiple myeloma or other hematological malignancies by disrupting multiple pathways critical for cancer cell survival.5. **Bisantrene and PARP Inhibitors**: - **Olaparib**: For cancers with BRCA mutations or other DNA repair deficiencies, combining bisantrene with PARP inhibitors could exploit synthetic lethality and enhance cell killing.6. **Bisantrene and Anti-Angiogenic Agents**: - **Bevacizumab**: Targeting angiogenesis along with bisantrene’s antitumor effects could be beneficial in solid tumors by disrupting the blood supply and direct tumor cell killing.7. **Bisantrene and CDK4/6 Inhibitors**: - **Palbociclib**: This combination might be effective in hormone receptor-positive breast cancer or other cancers reliant on the cell cycle for proliferation.8. **Bisantrene and Immunomodulatory Drugs (IMiDs)**: - **Lenalidomide**: Combining bisantrene with drugs that modulate the immune system could enhance anti-tumor immunity, particularly in hematological cancers.Preclinical studies and early-phase clinical trials are crucial to validate these combinations and determine their safety and efficacy profiles. Such combinations offer the potential to leverage the unique properties of bisantrene and enhance its therapeutic impact across various cancer types [oai_citation:3,Race Oncology’s new study highlights bisantrene's efficacy in treatment for acute myeloid leukemia | ASX:RAC, OTC:RAONF](do not advertise external links/companies/news/1042478/race-oncology-s-new-study-highlights-bisantrene-s-efficacy-in-treatment-for-acute-myeloid-leukemia-1042478.html) [oai_citation:4,Race Executes Contract to Commence Phase 2 Extramedullary AML Trial – Race Oncology](https://raceoncology.com/race-executes-contract-to-commence-phase-2-extramedullary-aml-trial/).